CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines

Blood

Volumn 95, Issue 3, 2000, Pages 1039-1046

  Teoh, G ^b   Tai, Y T ^b   Urashima, M ^b   Shirahama, S ^b   Matsuzaki, M ^b   Chauhan, D ^b   Treon, S P ^b   Raje, N ^b   Hideshima, T ^b   Shima, Y ^b   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; LUCIFERASE; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MISSENSE MUTATION; MYELOMA CELL; PRIORITY JOURNAL; REPORTER GENE; RIBONUCLEASE PROTECTION ASSAY; TEMPERATURE SENSITIVE MUTANT; TRANSACTIVATION; WESTERN BLOTTING;

EID: 12944283267     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.1039.003k02_1039_1046     Document Type: Article

References (42)

1. Rousset F, Garcia E, Banchereau J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med. 1991;173:705.
2. Banchereau J, Rousset F. Growing human B lymphocytes in the CD40 system. Nature. 1991;353: 678.
3. Spriggs MK, Armitage RJ, Strockbine L, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med. 1992;176:1543.
4. Clark EA, Shu GL, Luscher B, et al. Activation of human B cells: comparison of the signal transduced by IL-4 to four different competence signals. J Immunol. 1989;143:3873.
5. Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood. 1996;88:2219.
6. Urashima M, Chauhan D, Hatziyanni M, et al. CD40 ligand triggers interleukin-6 mediated B cell differentiation. Leuk Res. 1996;20:507.
7. Westendorf JJ, Ahmann GJ, Armitage RJ, et al. CD40 expression in malignant plasma cells: role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 1994;152:117.
8. Tong AW, Zhang BQ, Mues G, Solano M, Hanson T, Stone MJ. Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood. 1994;84:3026.
9. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995; 85:1903.
10. Planken EV, Dijkstra NH, Willemze R, Kluin-Nelemans JC. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the "CD40 system." Leukemia. 1996;10:488.
11. Tong AW, Stone MJ. CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity. Leuk Lymphoma. 1996; 21:1.
12. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta1: differential effects or multiple myeloma versus normal B cells. Blood 87:1928, 1996
13. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res. 1996;56:1909.
14. Bergamo A, Bataille R, Pellat-Deceunynck C. CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol. 1997;97:652.
15. Teoh G, Urashima M, Greenfield EA, et al. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest. 1998;101:1379.
16. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993; 82:3712.
17. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994;84:2269.
18. Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995;86:3151.
19. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87:1104.
20. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997; 11:27.
21. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997; 159:2212.
22. Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 1997;3:1017.
23. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227.
24. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997;15:837.
25. Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2 dependent and independent apoptosis in multiple myeloma cells. Oncogene. In press.
26. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:3435.
27. Yonish-Rouach E, Grunwald D, Wilder S, et al. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol. 1993;13:1415.
28. Urashima M, Teoh G, Chauhan D, et al. Interleukin-6 overcomes p21 WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood. 1997;90:279.
29. Margulies L, Sehgal PB. Modulation of the human interleukin-6-promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J Biol Chem. 1993;268:15,096.
30. Wang L, Rayanade RJ, Garcia D, Patel K, Pan H, Sehgal PB. Modulation of interleukin-6-induced plasma protein secretion in hepatoma cells by p53 species. J Biol Chem. 1995;270:23,159.
31. Rayanade RJ, Ndubuisi MI, Ellinger JD, Sehgal PB. Regulation of IL-6 signaling by p53: STAT3-and STAT5-masking in p53-Val135-containing human hepatoma Hep3B cell lines. J Immunol. 1998;161:325.
32. Teoh G, Urashima M, Ogata A, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997; 90:1982.
33. Gyllensten UB, Erlich HA. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci U S A. 1988; 85:7652.
34. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817.
35. Jia LQ, Osada M, Ishioka C, et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog. 1997;19:243.
36. Chuang JY, Lin CT, Wu CW, Lin YS. A movable and regulable inactivation function within the central region of a temperature-sensitive p53 mutant. J Biol Chem. 1995;270:23,899.
37. Mazars GR, Portier M, Zhang XG, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015.
38. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science. 1990;249:1046.
39. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990;249: 1049.
40. Unger T, Nau MM, Segal S, Minna JD. p53: a Iransdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 1992;11:1383.
41. Park DJ, Nakamura H, Chumakov AM, et al. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene. 1994;9:1899.
42. Portier M, Moles JP Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539.